Trial Profile
Durvalumab (MEDI4736) and Olaparib (AZD2281) for Treatment of Biochemically Recurrent Prostate Cancer in Men Predicted to Have a High Neoantigen Load: A Multicenter Pilot Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Jan 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Olaparib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 19 Jan 2024 Planned End Date changed from 30 Apr 2026 to 6 Jun 2025.
- 19 Jan 2024 Planned primary completion date changed from 30 Apr 2025 to 6 Jun 2024.
- 19 Jan 2024 Status changed from recruiting to active, no longer recruiting.